Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 6,052,631 of its common shares, which includes the full exercise of the underwriters' option to purchase 789,473 additional common shares, at a public offering price of $47.50 per s ...